Skip to main content
Olema Pharmaceuticals, Inc. logo

Olema Pharmaceuticals, Inc. - Investor Relations & Filings

Listed IPO Oct 2020
Ticker · OLMA ISIN · US68062P1066 US Manufacturing
Open in API
Filings indexed 511 across all filing types
Latest filing 2026-02-04 Director's Dealing
Country US United States of America
Listing US OLMA · 3 venues

About Olema Pharmaceuticals, Inc.

https://olema.com/

Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women's cancers. The company concentrates on endocrine-driven diseases, with a primary emphasis on breast cancer. Its lead product candidate, palazestrant (OP-1250), is an oral complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD). Palazestrant is under investigation in clinical trials as a potential treatment for patients with ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema is advancing a pipeline of drug candidates with the goal of developing improved therapeutic options for cancer patients.

Recent filings

Filing Released Lang Actions
4 Filing
Director's Dealing
2026-02-04 English
8-K Filing
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated January 27, 2026, reporting the departure of a key executive, Shane Kovacs, the Chief Operating and Financial Officer, and the appointment of the CEO as interim principal financial officer. The content focuses on management changes, including details of a separation agreement and interim appointment. There are no financial statements or earnings data presented, nor is this a report or announcement of financial results. The primary subject is a change in senior management personnel. According to the filing definitions, announcements of changes in the company's board of directors or senior management fall under Board/Management Information (MANG). The document length is about 5,031 characters, which is sufficient for a full announcement rather than a brief notice. Therefore, the appropriate classification is MANG with high confidence.
2026-01-30 English
4 Filing
Director's Dealing
2026-01-21 English
Regulatory Filings 2026
Regulatory Filings
2026-01-20 English
Director's Dealing 2026
Director's Dealing
2026-01-17 English
Director's Dealing 2026
Director's Dealing
2026-01-16 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.